Artal Group’s Immunic IMUX Stock Holding History

Artal Group’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-127,471	Closed	-$1.9M	–	127
2023 Q1	$1.9M	Hold	127,471	–	–	0.11%	81
2022 Q4	$1.78M	Buy	127,471 +57,471	+82%	+$1.57M	0.1%	93
2022 Q3	$2.21M	Hold	70,000	–	–	0.09%	92
2022 Q2	$2.43M	Hold	70,000	–	–	0.13%	88
2022 Q1	$7.91M	Hold	70,000	–	–	0.33%	58
2021 Q4	$6.7M	Hold	70,000	–	–	0.18%	87
2021 Q3	$6.2M	Hold	70,000	–	–	0.14%	106
2021 Q2	$8.58M	Hold	70,000	–	–	0.17%	95
2021 Q1	$11.2M	Hold	70,000	–	–	0.2%	96
2020 Q4	$10.7M	Sell	70,000 -10,000	-13%	-$1.8M	0.23%	85
2020 Q3	$14.9M	Buy	80,000 +20,000	+33%	+$3.28M	0.36%	59
2020 Q2	$7.27M	Sell	60,000 -3,002	-5%	-$305K	0.2%	87
2020 Q1	$3.81M	Hold	63,002	–	–	0.16%	85
2019 Q4	$6.11M	Buy	+63,002	New	+$5.24M	0.24%	65
2018 Q3	–	Sell	-2,500	Closed	-$6.85M	–	114
2018 Q2	$6.85M	Hold	2,500	–	–	0.15%	58
2018 Q1	$6.8M	Buy	2,500 +312	+14%	+$716K	0.09%	59
2017 Q4	$5.21M	Hold	2,188	–	–	0.08%	69
2017 Q3	$4.42M	Hold	2,188	–	–	0.08%	68
2017 Q2	$2.54M	Hold	2,188	–	–	0.04%	90
2017 Q1	$3.5M	Buy	+2,188	New	+$4.01M	0.08%	73

Other funds holding IMUX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Artal Group's IMUX Position: Q2 2023 in Review

Artal Group sold out of Immunic (IMUX) in Q2 2023, closing a stake of 127,471 shares — an estimated $1.9M sold.

Artal Group first reported a position in IMUX in Q1 2017 and held it in 20 quarters. The position peaked at $14.9M in Q3 2020. 63 funds tracked by Wall St. Rank hold IMUX as of Q2 2023.

Artal Group reported no remaining Immunic position as of Q2 2023 after selling out during the quarter.
Artal Group sold 127,471 Immunic shares in Q2 2023, an estimated $1.9M.
Artal Group first reported a position in Immunic in Q1 2017 and held it in 20 quarters.
Artal Group's Immunic position peaked at $14.9M in Q3 2020.
63 funds tracked by Wall St. Rank held Immunic as of Q2 2023.

Based on Artal Group's 13F filing for Q2 2023, filed 11 Aug 2023.